Table 2.
Comparison of the frequency of mucocutaneous side effects of isotretinoin between case and control groups.
| |
Isotretinoin group (%) |
Isotretinoin + omega-3 group (%) |
P value |
|---|---|---|---|
| Dry lips | |||
| Baseline | 0 | 0 | |
| Week 4 | 78.7 | 58 | 0.030∗ |
| Week 8 | 64.8 | 50 | 0.041∗ |
| Week 12 | 44.4 | 26 | 0.044∗ |
| Week 16 | 25.6 | 14 | 0.130 |
| Dry nose | |||
| Baseline | 0 | 0 | |
| Week 4 | 33.3 | 12 | 0.010∗ |
| Week 8 | 24.1 | 10 | 0.003∗ |
| Week 12 | 14 | 2 | 0.020∗ |
| Week 16 | 11.1 | 0 | 0.001∗ |
| Dry skin | |||
| Baseline | 0 | 0 | |
| Week 4 | 40.7 | 16 | 0.003∗ |
| Week 8 | 22.2 | 10 | 0.021∗ |
| Week 12 | 18.5 | 8 | 0.002∗ |
| Week 16 | 11.1 | 2 | 0.013∗ |
| Dry eyes | |||
| Baseline | 0 | 0 | |
| Week 4 | 13 | 4 | 0.046∗ |
| Week 8 | 9.3 | 6 | 0.533 |
| Week 12 | 3.7 | 0 | 0.169 |
| Week 16 | 0 | 0 | 1.00 |
∗ P values less than 0.05 were considered significant.